HC Wainwright Reiterates Buy Rating for Obseva (NASDAQ:OBSV)

Share on StockTwits

Obseva (NASDAQ:OBSV)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Monday, Marketbeat Ratings reports. They currently have a $36.00 target price on the stock, down from their prior target price of $44.00.

Several other research firms have also recently issued reports on OBSV. Credit Suisse Group cut shares of Obseva from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $16.00 to $4.00 in a research note on Friday, November 8th. Royal Bank of Canada reissued a “buy” rating on shares of Obseva in a research report on Sunday, August 11th. BidaskClub raised shares of Obseva from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 30th. Zacks Investment Research upgraded shares of Obseva from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Finally, Wedbush reaffirmed a “buy” rating and issued a $38.00 target price on shares of Obseva in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $22.75.

OBSV opened at $4.52 on Monday. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.38. The firm has a market cap of $196.02 million, a P/E ratio of -2.37 and a beta of 0.59. Obseva has a 52 week low of $2.37 and a 52 week high of $15.93. The business’s fifty day simple moving average is $5.40 and its 200 day simple moving average is $8.92.

Obseva (NASDAQ:OBSV) last announced its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.19. As a group, equities analysts expect that Obseva will post -2.77 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC lifted its position in Obseva by 263.6% during the second quarter. Cubist Systematic Strategies LLC now owns 3,272 shares of the company’s stock worth $37,000 after buying an additional 2,372 shares during the period. Morgan Stanley grew its holdings in Obseva by 358.6% in the 2nd quarter. Morgan Stanley now owns 3,100 shares of the company’s stock valued at $35,000 after buying an additional 2,424 shares during the period. Capital Investment Advisory Services LLC acquired a new position in shares of Obseva during the 2nd quarter valued at about $40,000. Renaissance Technologies LLC increased its stake in shares of Obseva by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 79,600 shares of the company’s stock valued at $900,000 after acquiring an additional 5,600 shares during the last quarter. Finally, Wedbush Securities Inc. increased its stake in shares of Obseva by 54.2% during the 3rd quarter. Wedbush Securities Inc. now owns 40,108 shares of the company’s stock valued at $334,000 after acquiring an additional 14,100 shares during the last quarter. Hedge funds and other institutional investors own 61.47% of the company’s stock.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Featured Story: What is a Candlestick Chart?

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Clean Yield Group Lowers Stock Holdings in Quest Diagnostics Inc
Clean Yield Group Lowers Stock Holdings in Quest Diagnostics Inc
Clean Yield Group Decreases Stock Position in General Electric
Clean Yield Group Decreases Stock Position in General Electric
Clean Yield Group Grows Stock Holdings in iShares Core S&P Mid-Cap ETF
Clean Yield Group Grows Stock Holdings in iShares Core S&P Mid-Cap ETF
iShares Agency Bond ETF  Shares Bought by Clean Yield Group
iShares Agency Bond ETF Shares Bought by Clean Yield Group
Clean Yield Group Has $452,000 Position in First Solar, Inc.
Clean Yield Group Has $452,000 Position in First Solar, Inc.
Clean Yield Group Buys 2,884 Shares of AFLAC Incorporated
Clean Yield Group Buys 2,884 Shares of AFLAC Incorporated


 
© 2006-2020 Zolmax.